We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Vaxzevria

News List

Highlights of the May 2021 Pharmacovigilance Risk Assessment Committee (PRAC) meeting europeanpharmaceuticalreview
May 11, 2021
In its May meeting, the EMA’s drug safety committee (PRAC) concluded two safety signal reviews for COVID-19 vaccines and began several more.
Inactivated COVID-19 vaccine candidate enters comparative immunogenicity trial europeanpharmaceuticalreview
April 26, 2021
The Phase III trial aims to demonstrate that Valneva’s VLA2001 is more immunogenic than AstraZeneca’s conditionally approved COVID-19 vaccine, Vaxzevria.
Highlights of the EMA’s drug safety committee April meeting europeanpharmaceuticalreview
April 14, 2021
In the April meeting the Pharmacovigilance Risk Assessment Committee began two new reviews of adverse events that could be caused by COVID-19 vaccines.

Previous page 1 2 3 Next page